503B outsourcing facilities and semaglutide: registration, inspection and GLP-1 records

Which 503B outsourcing facilities make semaglutide?

FDA does not publish which drugs each registered outsourcing facility makes, and on April 1, 2026 it stated that semaglutide is on neither the 503B bulks list nor its drug shortage list, the two routes for outsourcing facilities to compound from bulk semaglutide. 6 facilities on FDA’s list of 100 (updated Nov 6, 2026) also appear in FDA warning letters or recall reports naming GLP-1 drugs in this index.

A record here is not a recommendation or a rating. This site does not rank facilities.

Apollo CareColumbia, MOJul 28, 2026Yes011
Apothecary Pharma, LLCCary, NCSep 2, 2026Yes11
GenoGenix LLCRaton, FLJul 18, 2025Yes14
PQ Pharmacy LLCBrooksville, FLJun 1, 2026Yes10
ProRx LLCExton, PASep 19, 2025Yes214
Tailstorm Health Inc.Chandler, AZAug 28, 2026Yes10

The full list of 100 facilities, each with its own page of registration dates and FDA inspections, is on the 503B facilities page.

FDA’s 503B list does not name products, but outsourcing facilities that assign NDCs report their compounded products to FDA’s NDC Directory: Which outsourcing facilities list compounded semaglutide or tirzepatide with FDA?

FDA’s statements on outsourcing facilities and semaglutide

Common questions

Can a public record say which 503B outsourcing facility to use for semaglutide?

No. A record cannot rank facilities, and this site does not. What the records show is each facility’s FDA registration dates, last inspection, Form 483 status and dated FDA actions, on each facility’s page.

What is a 503B outsourcing facility?

A compounder registered with FDA under section 503B of the Federal Food, Drug, and Cosmetic Act. Outsourcing facilities are subject to FDA inspection and current good manufacturing practice requirements, and FDA lists each one with its last inspection date.

What is a Form FDA 483?

A form FDA investigators issue at the end of an inspection listing conditions they observed that may violate the law. It is not a final agency determination.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.